Skip to main content
    A

    Azitra Inc (AZTR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $0.07
    +0.00 (+0.00%)

    Market Cap: $4.33M

    Last updated: Oct 14, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    67%(6/9)
    Avg Surprise
    -57.50%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.02
    Range$-0.02 - $-0.02
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.04+50.0%
    60d ago$-0.04+50.0%
    30d ago$-0.04+50.0%
    7d ago$-0.04+50.0%
    Current$-0.02
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.06
    Range$0.06 - $0.06
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.06---
    Sep 26EST
    		-$-0.02---
    Jun 26
    Reported Aug 12
    		$-0.17$-0.21+19.05%Beat+85.8%
    Mar 26
    Reported May 12
    		$-0.25$-0.04-525.00%Miss-8.7%
    Dec 25
    Reported Mar 2
    		$-1.17$-0.32-265.63%Miss+44.0%
    Sep 25
    Reported Nov 12
    		$-0.67$-0.77+12.99%Beat+79.7%
    Jun 25
    Reported Aug 11
    		$-1.20$-1.40+14.29%Beat+93.4%
    Mar 25
    Reported May 13
    		$-0.23$0.00N/ABeat+94.7%
    Dec 24
    Reported Mar 21
    		$-2.09$-3.33+37.24%Beat-107.5%
    Sep 24
    Reported Nov 12
    		$-3.30$-3.20-3.13%Miss-1962.5%
    Jun 24
    Reported Aug 12
    		$-18.25$-21.45+14.92%Beat+78.2%
    Mar 24
    Reported Apr 29
    		$-4.36$0.00N/ABeat-
    Dec 23
    Reported Mar 15
    		$27.97$-35.96+177.78%Beat-
    Sep 23
    Reported Nov 14
    		$-0.16N/AN/ABeat-
    Jun 23
    Reported Aug 14
    		$-83.78N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.03EV/EBITDAN/A
    Price/FCF-0.12xFCF Yield-809.66%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-256.70%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage-1165.91x
    Current Ratio4.86xQuick Ratio4.86x
    Trading Statistics
    Beta-1.04Avg Volume838.19K
    52-Week High$1.0952-Week Low$0.05

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.12
    SMA 20$0.14
    SMA 50$0.15
    SMA 200$0.20
    EMA 10$0.11
    EMA 20$0.13
    EMA 50$0.15
    EMA 200$0.29

    MACD

    Line: -0.02Signal: -0.01Hist: -0.01

    ADX

    ADX: 39.3+DI: 6.6-DI: 48.7

    Aroon & PSAR

    Aroon Up12.0
    Aroon Down96.0
    PSAR$0.13

    Bollinger Bands

    Upper Band$0.20
    Lower Band$0.08
    %B Position8760%(Upper)
    Band Width-0.06

    RSI (14-Day)

    Oversold
    19.6

    Momentum Oscillators

    Stoch %K11.7
    Stoch %D11.1
    Williams %R-84.0
    ROC (10d)-48.0%
    Momentum-0.07
    CCI (20d)-210.7
    MFI (14d)21.7

    Volatility Measures

    ATR (14d)$0.02(21.3%)
    StdDev (20d)0.03
    Hist Vol169.3%(High)

    Volume Flow

    VWAP$0.07
    OBV1.2B
    AD Line16.3B
    CMF (20d)-0.308

    Volume Metrics

    Avg Vol (20d)800.1K
    Vol RatioN/A
    VWMA (20d)$0.13

    Pivot Points

    R3$0.18
    R2$0.15
    R1$0.11
    Pivot Point$0.08
    S1$0.04
    S2$0.01
    S3$-0.03

    Advanced Oscillators

    TSI-37.49
    Ultimate Osc28.7
    KST-232.05

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$7.49M$0$7,500$0$90,000$310,700
    Cost of Revenue$0$0$113,104$0$0$0$115,748$0$0$0N/A$0
    Gross Profit$0$0$-113,104$0$0$0$-115,748$0$7,500$0$90,000$310,700
    Operating Expenses$3.42M$3.93M$2.23M$2.77M$2.87M$3.10M$2.43M$2.93M$2.67M$2.96M$2.56M$2.30M
    R&D$1.35M$1.56M$1.00M$1.18M$1.40M$1.25M$1.12M$1.02M$1.12M$1.47M$1.51M$548,524
    SG&A$2.07M$2.37M$1.22M$1.59M$1.47M$1.85M$1.32M$1.91M$1.55M$1.49M$1.05M$1.76M
    Operating Income$-3,419,168$-3,933,924$-2,226,591$-2,768,484$-2,871,352$-3,100,238$-2,434,156$-2,929,207$-2,660,280$-2,961,497$-2,470,477$-1,993,732
    Interest Income$74,661$14,719$12,761$4,823$15,461$37,164$51,287$47,389$16,268$7,609$394$634
    Interest Expense$1,365$3,411$5,454$372$468$1,293$5,612$3,851$1,782$915$997$710
    Income Before Tax$-3,347,660$-3,927,240$-2,225,185$-2,764,528$-2,888,993$-3,068,345$-2,384,102$-1,009,491$-2,631,993$-2,932,875$-2,446,191$-1,943,289
    Income Tax Expense$0$0$8,319$0$0$0$9,031$0$0$0$7,593$0
    Net Income$-3,347,660$-3,927,240$-2,233,504$-2,764,528$-2,888,993$-3,068,345$-2,393,133$-1,009,491$-2,631,993$-2,932,875$-2,453,784$-1,943,289
    EBITDA$-3,307,394$-3,821,895$-2,119,388$-2,656,978$-2,793,416$-2,986,944$-2,314,029$-949,396$-2,532,538$-2,824,656$-2,282,479$-1,830,709
    EBIT$-3,420,956$-3,938,548$-2,232,492$-2,768,979$-2,904,040$-3,104,359$-2,429,777$-1,053,029$-2,646,479$-2,939,569$-2,390,980$-1,943,213
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about AZTR

    News

    Azitra advances skin rash treatment trial to second cohort

    Azitra Inc. has announced that its Phase 1/2 clinical trial for ATR04-484, a treatment for EGFR inhibitor-associated skin rash, will progress to Cohort 2 after a successful safety review of Cohort 1 data. The trial...

    Investing.com•10/2/26•Bullish

    Azitra advances skin rash treatment trial to second cohort By Investing.com

    Azitra Inc. has advanced its Phase 1/2 clinical trial for ATR04-484, a treatment for EGFR inhibitor-associated skin rash, to Cohort 2 after a safety review committee approved Cohort 1 data. The trial...

    Investing.com Nigeria•10/2/26•Bullish

    Azitra advances ATR04-484 trial for cancer treatment skin rash after positive safety review

    Azitra, Inc. has successfully completed Cohort 1 of its Phase 1/2 trial for ATR04-484, a treatment for skin rash caused by EGFR inhibitors in cancer therapy. The safety review committee has approved progression to Cohort...

    Pluang•10/1/26•Bullish

    Azitra advances skin rash treatment trial to second cohort By Investing.com

    Azitra Inc. has announced that its Phase 1/2 clinical trial for ATR04-484, a treatment for EGFR inhibitor-associated skin rash...

    Investing.com Canada•10/1/26•Bullish

    Azitra, Inc. Advances ATR-04 Phase 1/2 Clinical Trial to Cohort 2 Following Safety Review Committee Clearance

    Azitra, Inc. announced the progression of its ATR-04 Phase 1/2 clinical trial to Cohort 2 after the safety review committee cleared Cohort 1. The trial evaluates ATR-04 for EGFR inhibitor-associated skin rash...

    PR Newswire•10/1/26•Bullish

    AZTR Valuation and Fair Value

    P/E
    -0.0x
    P/FCF
    -0.1x
    P/B
    0.2x
    See GNG's fair value

    AZTR Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -256.7%
    FCF yield
    -809.7%

    AZTR Competitors

    CompanyTicker
    Liminatus Pharma, Inc. Class A Common StockLIMN
    Jupiter Neurosciences, Inc. Common StockJUNS
    Dermata Therapeutics IncDRMA
    cbdMD IncYCBD
    NuCana PLCNCNA
    PharmaCyte Biotech IncPMCB
    Enlivex Therapeutics LtdENLV
    NanoVibronix IncNAOV

    Sector: Healthcare

    AZTR Bull Case vs Bear Case

    Bear case

    • AZTR's quarterly revenue changed -100.0% year over year.

    AZTR Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -101.5%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.02
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About AZTR

    Does AZTR pay dividends?

    Azitra Inc (AZTR) does not currently pay a regular dividend.

    What is AZTR's market cap?

    Azitra Inc (AZTR) has a market capitalization of $4.33M with a current stock price of $0.07.

    Related stocks

    Sector: Healthcare

    All stocks starting with A

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In